Loading
A Seattle trial in 10 people with advanced melanoma testing the side effects and effect of their own laboratory-grown T cells given after cyclophosphamide, with IL-2. It ran from 2007 to 2012.
The registry describes a phase I/II study of autologous CD8+ antigen-specific T-cell clones following cyclophosphamide conditioning, with aldesleukin, in metastatic melanoma, started in September 2007, with primary completion in August 2010, completion in March 2012 and an actual enrolment of 10 (ClinicalTrials.gov NCT00553306). Cassian Yee is listed as principal investigator and Fred Hutchinson Cancer Center as sponsor (ClinicalTrials.gov NCT00553306). No results are posted.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/